List of Excipients in Branded Drug CLINDAMYCIN PALMITATE HYDROCHLORIDE

Generic Drugs Containing CLINDAMYCIN PALMITATE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Padagis US LLC	clindamycin palmitate hydrochloride	0574-0129	DIMETHICONE
Padagis US LLC	clindamycin palmitate hydrochloride	0574-0129	ETHYLPARABEN
Padagis US LLC	clindamycin palmitate hydrochloride	0574-0129	ICODEXTRIN
Padagis US LLC	clindamycin palmitate hydrochloride	0574-0129	POLOXAMER 188
Padagis US LLC	clindamycin palmitate hydrochloride	0574-0129	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in CLINDAMYCIN PALMITATE HYDROCHLORIDE?

# Of NDCs	Excipient
4	CHERRY
1	DEXTRIN, CORN
6	DIMETHICONE
1	DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER
13	ETHYLPARABEN

Clindamycin Palmitate Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Clindamycin palmitate hydrochloride is an established oral pediatric formulation with limited active-drug patent protection and substantial opportunity for differentiation through taste masking, reconstitution performance, preservative strategy, dosing flexibility, and supply-chain economics. The preferred commercial platform remains a dry powder for oral suspension because the palmitate ester has limited aqueous solubility and the dry product offers better stability than a ready-to-use liquid.

What is the commercial role of clindamycin palmitate hydrochloride?

Clindamycin palmitate hydrochloride is the oral prodrug salt used to deliver clindamycin in pediatric patients. After administration, it is hydrolyzed to active clindamycin. The reference product, Cleocin Pediatric, is supplied as a powder that is reconstituted to an oral suspension containing 75 mg of clindamycin per 5 mL [1].

The product is used for susceptible bacterial infections, including infections caused by anaerobic organisms and certain gram-positive bacteria. Its main commercial limitations are:

• Bitter taste and pediatric acceptability.
• Multiple daily doses.
• Risk of gastrointestinal adverse events, including Clostridioides difficile-associated diarrhea.
• Competition from low-cost clindamycin capsules, injectable clindamycin phosphate, and alternative antibiotics.
• Dependence on reliable pediatric liquid supply.
• Formulation complexity caused by the poorly water-soluble palmitate ester.

Clindamycin is not a biologic. Biosimilar competition is therefore irrelevant. Competitive pressure comes from generic oral suspensions, capsules, alternative antibiotics, hospital injectables, and reformulated pediatric products.

What excipients are used in clindamycin palmitate hydrochloride suspension?

The reference product uses a conventional pediatric suspension platform built around a high-solids powder, sweetening, flavoring, coloring, suspension control, and antimicrobial preservation. FDA labeling identifies inactive ingredients that include sucrose, sodium saccharin, methylparaben, propylparaben, and flavoring components. Exact excipient composition can vary by presentation and manufacturer [1].

Typical excipient functions are shown below.

Excipient function	Commercial purpose	Key development issue
Sucrose	Sweetness, bulk, mouthfeel	Caloric load, dental concerns, osmolality
Sodium saccharin	High-intensity sweetener	Aftertaste and pediatric acceptability
Flavor	Masks bitterness and medicinal notes	Flavor compatibility, regional preference
Methylparaben	Antimicrobial preservation	Regulatory and parental preference concerns
Propylparaben	Preservative synergy	Solubility and preservative distribution
Suspending agent	Controls sedimentation and redispersion	Viscosity, pourability, dose uniformity
Wetting agent	Improves powder dispersion	Foaming and taste
Colorant	Product identification and acceptability	Dye sensitivity and market restrictions
Buffer or pH modifier	Controls hydrolysis and preservative performance	Stability, taste, compatibility
Glidant or processing aid	Improves powder flow	Powder uniformity and reconstitution

The product should be developed as a suspension rather than a true solution unless a new salt, cosolvent system, or solubilizing technology is used. A solution approach may create a more convenient product but increases the risk of chemical degradation, precipitation, preservative instability, and taste exposure.

Which excipient strategy is best for a new generic product?

The strongest baseline strategy is a low-complexity dry powder for reconstitution with a reduced excipient burden and a robust taste-masking system. A generic sponsor should prioritize pharmaceutical equivalence, bioequivalence, stability, and reproducible reconstitution over aggressive excipient novelty.

A practical target profile is:

• 75 mg/5 mL after reconstitution.
• Two or more bottle sizes to cover pediatric treatment courses.
• Simple room-temperature storage before and after reconstitution, if supported by stability data.
• Rapid wetting and uniform dispersion.
• Low sedimentation with easy redispersion.
• Accurate dosing using an oral syringe.
• Minimal foaming.
• Acceptable taste after repeated dosing.
• Preservative effectiveness across the labeled in-use period.
• Low risk of excipient-related gastrointestinal intolerance.

Excipient selection should follow the FDA Inactive Ingredient Database and the inactive ingredients used in the reference product or previously approved oral suspensions. A materially different excipient system may require additional justification under the ANDA pathway, particularly when the excipient affects absorption, tolerability, preservation, or product performance [2].

Sucrose versus alternative sweeteners

Sucrose provides bulk, sweetness, and a familiar pediatric mouthfeel. It also increases density and can help create a commercially acceptable suspension. Its disadvantages include sugar content, dental concerns, and reduced suitability for children with dietary restrictions.

Potential alternatives include:

• Sorbitol or xylitol for reduced-sugar positioning.
• Sucralose for high-intensity sweetness.
• Acesulfame potassium in combination with another sweetener.
• Aspartame, subject to phenylalanine labeling requirements.
• Polyols combined with flavor modifiers.

A sugar-free product could support hospital, institutional, and caregiver demand, but the formulation may become more hygroscopic and may require tighter control of viscosity, water activity, microbial preservation, and powder flow. A reduced-sugar product is more commercially defensible than a conventional copy if it retains equivalent dosing and acceptable stability.

Parabens versus alternative preservation

Methylparaben and propylparaben are established preservatives for oral liquids. Their use can reduce development risk because they are familiar in pediatric liquid products and can support multidose packaging.

A paraben-free formulation could be differentiated through:

• Potassium sorbate or sorbic acid.
• Sodium benzoate or benzoic acid.
• A lower-water-activity system.
• Single-dose or unit-dose packaging.
• A preservative-free product with validated in-use microbiological control.

Preservative substitution is not automatically an improvement. Sodium benzoate and related systems are pH-dependent, while sorbate systems can affect taste and may require acidic conditions. Preservative-free multidose packaging requires strong container-closure and microbiological data. A unit-dose powder or single-use reconstitution format may offer a clearer regulatory and commercial rationale than simply replacing parabens.

What formulation patents could protect clindamycin palmitate hydrochloride?

The active ingredient is old, and the primary commercial opportunity is formulation and delivery-system protection rather than composition-of-matter protection.

Potentially protectable subject matter includes:

1. A specific taste-masking system.
2. A sugar-free or low-sugar suspension.
3. A preservative-free multidose product.
4. A dry powder with improved reconstitution speed.
5. A suspension with improved redispersion after storage.
6. A high-concentration formulation that reduces dosing volume.
7. A unit-dose sachet or cup.
8. A formulation with reduced bitterness after administration.
9. A formulation with improved stability under high temperature and humidity.
10. A delivery system that improves dose accuracy through a supplied oral syringe or calibrated dosing device.

A formulation patent must define a real technical distinction. Broad claims covering clindamycin palmitate hydrochloride plus ordinary sweeteners, flavors, or suspension agents would face substantial validity and obviousness risk. Stronger claims would link excipient ratios or process parameters to measurable performance, such as:

• Reduced bitterness in a validated sensory panel.
• Improved assay retention after reconstitution.
• Reduced particle growth.
• Faster wetting time.
• Lower sedimentation volume.
• Improved redispersion after defined storage.
• Preservative effectiveness under compendial testing.
• Reduced dose variability across the bottle.

How strong is the patent estate for clindamycin palmitate hydrochloride?

The legacy patent estate is weak as a barrier to generic entry. Clindamycin has been marketed for decades, and the major commercial product is exposed to generic competition. The relevant patent value lies in narrow formulation, packaging, manufacturing, and device claims rather than in the active pharmaceutical ingredient.

A new formulation patent could have commercial value if it produces a meaningful label or market distinction. It would have limited value if it covers only an interchangeable excipient substitution that an ANDA applicant can design around.

What is the Orange Book status of clindamycin palmitate hydrochloride?

The FDA Orange Book lists approved clindamycin products and identifies patent and exclusivity information for products where applicable. Cleocin Pediatric is an established reference product, but the commercial market is primarily generic and does not depend on an active, blocking patent estate [3].

For a new generic sponsor, the likely regulatory pathway is an ANDA referencing the applicable listed drug. The submission would generally rely on pharmaceutical equivalence and bioequivalence rather than a clinical efficacy program. A novel formulation with materially different excipients, concentration, delivery technology, or clinical use may require a 505(b)(2) application instead of an ANDA [4].

When does clindamycin palmitate hydrochloride lose exclusivity?

The product lost practical market exclusivity long ago. It is an established generic product with no meaningful new-drug exclusivity barrier controlling ordinary oral suspension entry.

The relevant commercial dates are therefore not a single future patent expiration date. They are:

Exclusivity element	Commercial status
Composition-of-matter protection	Expired
Original new-drug exclusivity	Expired
Pediatric exclusivity	Not a current barrier
Formulation patent barrier	No broadly blocking barrier identified for the established reference product
ANDA generic entry	Mature and established
New formulation exclusivity	Potentially available only for a qualifying new product
Orphan exclusivity	Not applicable to the general product

A sponsor seeking exclusivity would need to create a new product profile, such as a novel concentration, delivery system, or clinically meaningful formulation. A routine generic suspension would not receive new-drug exclusivity merely because it uses different excipients.

Are Paragraph IV challenges relevant to clindamycin palmitate hydrochloride?

Paragraph IV litigation is not the principal entry issue for this mature product. A Paragraph IV certification is relevant only when an ANDA applicant addresses a listed patent in the Orange Book. If no active patent covers the referenced product, the applicant would generally rely on a Paragraph III certification or a section viii statement, depending on the product and labeling circumstances [4].

Potential disputes could still arise from:

• A newly listed formulation patent.
• A device patent covering a dosing system.
• A method-of-use patent tied to a specific indication.
• A 505(b)(2) product attempting to obtain differentiated labeling.
• Patent claims directed to a narrow high-concentration or preservative-free formulation.

The litigation risk is more likely to concern a newly commercialized formulation than the legacy clindamycin palmitate hydrochloride product itself.

What method-of-use patents could cover clindamycin palmitate hydrochloride?

Method-of-use patent opportunities are limited because clindamycin has established uses and broad antibacterial indications. Narrower claims could address:

• A defined pediatric population.
• A specific infection caused by a susceptible organism.
• A dosing regimen that reduces adverse events.
• Use in patients unable to swallow capsules.
• A formulation-specific administration schedule.
• Combination use with another treatment.

Method-of-use claims would need commercially meaningful labeling and enforcement leverage. A generic applicant may use a section viii statement to omit a patented indication if the remaining label supports approval without the patented use. Broad treatment claims for established infections would face significant validity and freedom-to-operate challenges.

Which companies are challenging or competing with clindamycin palmitate hydrochloride?

Competition comes from multiple product classes rather than from one branded challenger.

Competitor class	Examples	Competitive impact
Generic clindamycin oral suspension	Multiple ANDA suppliers	Direct price and availability competition
Clindamycin capsules	Generic 75 mg, 150 mg, and 300 mg products	Lower-cost option for patients able to swallow capsules
Clindamycin phosphate injection	Generic injectable products	Hospital and severe-infection alternative
Pediatric alternative antibiotics	Amoxicillin, cephalexin, azithromycin and others	Reduces use where narrower or better-tolerated options are available
Compounded liquids	Pharmacy-compounded clindamycin products	Local supply option but variable availability and economics
Specialty pediatric formulations	Potential sugar-free or taste-masked products	Differentiated pricing and channel access

The most defensible commercial position is not a standard generic bottle. It is a product that solves a defined problem: poor taste, sugar exposure, dosing errors, short supply, high-volume administration, or storage limitations.

What commercial opportunities exist in clindamycin palmitate hydrochloride?

Sugar-free pediatric suspension

A sugar-free product could target children with diabetes, dental-risk concerns, dietary restrictions, or caregiver preference for reduced sugar. The formulation must maintain acceptable viscosity and taste without relying on sucrose as the primary bulking agent.

Commercial value would be highest if the product has:

• A clean excipient label.
• Strong taste performance.
• No artificial color.
• A dosing syringe.
• Stable post-reconstitution shelf life.
• Pediatric and institutional packaging.

High-concentration suspension

A higher concentration could reduce dosing volume and improve adherence. This opportunity has technical and regulatory risk because higher solids loading can worsen sedimentation, caking, viscosity, and dose nonuniformity.

A high-concentration product would need comparative data showing:

• Accurate dosing through the full bottle life.
• Easy redispersion.
• No excessive pouring force.
• Acceptable taste at higher drug loading.
• Equivalent exposure or an appropriate bioequivalence strategy.

Unit-dose powder or sachet

Unit-dose packaging can reduce microbial risk, eliminate the need for a preserved multidose liquid, and improve portability. It may be attractive for emergency departments, outpatient clinics, travel, and institutional dispensing.

The main barriers are packaging cost, reconstitution convenience, water requirements, and the need to demonstrate powder uniformity across sachets. A unit-dose presentation also creates an opportunity for premium pricing if it reduces pharmacy compounding or dispensing errors.

Ready-to-use liquid

A ready-to-use liquid could improve convenience but is less attractive as a first development target. The liquid must maintain chemical and microbiological stability over its shelf life, tolerate transport conditions, and preserve palatability. The palmitate ester and suspension system increase the risk of precipitation, settling, and potency drift.

A ready-to-use product may be commercially viable for hospital systems or specialty pediatric channels, but it typically requires a stronger formulation platform than a dry powder.

Device-enabled dosing

A supplied oral syringe, bottle adapter, or dose-marked closure can differentiate the product without changing the active ingredient. Device claims may create a secondary IP layer, although enforceability depends on whether the device is necessary for the formulation and included in the approved product.

The product should support the labeled dosing schedule and avoid confusing dose graduations. A 5 mL presentation should provide practical markings for common pediatric doses.

What manufacturing and intellectual-property barriers affect entry?

The main barriers are technical rather than patent-based.

Powder uniformity

Clindamycin palmitate hydrochloride must be uniformly distributed in a powder containing a large excipient mass. Segregation during blending, filling, transport, or bottle inversion can cause dose variability.

Critical controls include:

• Particle-size distribution.
• Bulk density matching.
• Blend uniformity.
• Flowability.
• Electrostatic behavior.
• Bottle fill accuracy.
• Moisture control.

Reconstitution performance

The powder must wet rapidly and disperse without persistent lumps. The formulation should specify a validated water-addition procedure and include container headspace sufficient for shaking.

Stability

Hydrolysis, moisture uptake, preservative distribution, flavor migration, and color changes can affect product quality. Stability studies should cover both the unopened powder and the reconstituted suspension under the labeled in-use period.

Taste masking

Taste masking is a commercial barrier because the palmitate ester and clindamycin-related degradation products may produce bitterness or medicinal notes. A successful formulation may combine sweetener, flavor, polymeric coating, particle engineering, and controlled release of dissolved drug in the oral cavity.

Geographic coverage

U.S. entry should be evaluated through the Orange Book, ANDA requirements, and FDA inactive ingredient rules. European and other markets may apply different rules for excipient acceptability, pediatric labeling, preservative use, and colorants. A globally deployable formulation should avoid excipients with market-specific restrictions where possible.

How should investors assess revenue exposure?

Legacy clindamycin palmitate hydrochloride revenue is exposed to generic pricing, hospital formulary substitution, and competition from capsules and alternative antibiotics. Public FDA records establish approval and labeling but do not provide a complete product-level revenue forecast. Commercial value depends on channel access, supply reliability, reimbursement, and whether the product offers a differentiated pediatric benefit.

A standard generic suspension is likely to compete primarily on:

• Cost of goods.
• Shortage avoidance.
• Distributor service levels.
• Bottle sizes.
• Contract pricing.
• Regulatory reliability.

A differentiated formulation can compete on:

• Reduced dosing volume.
• Better taste.
• Sugar-free positioning.
• Preservative-free or low-preservative design.
• Unit-dose convenience.
• Reduced dispensing and administration errors.

The most attractive opportunity is a modestly differentiated product with a conventional regulatory path, rather than a technically ambitious product that requires extensive clinical or 505(b)(2) development.

Key Takeaways

• Clindamycin palmitate hydrochloride is a mature, genericized pediatric antibiotic product.
• The active ingredient has no meaningful current composition-of-matter exclusivity.
• Formulation and delivery-system claims are more relevant than legacy active-ingredient patents.
• Dry powder for oral suspension remains the lowest-risk commercial platform.
• Taste masking, sugar reduction, preservative strategy, high concentration, and unit-dose packaging offer the clearest differentiation.
• A new formulation should use excipients with established regulatory precedent and assess FDA Inactive Ingredient Database status early.
• Paragraph IV litigation and biosimilar risk are not major barriers for the established product.
• Manufacturing risk centers on powder uniformity, reconstitution, moisture control, stability, preservation, and taste.
• A standard generic faces price competition; a differentiated pediatric product may support stronger channel positioning.
• The strongest IP strategy combines formulation performance claims with packaging or dosing-device protection.

FAQs

Is clindamycin palmitate hydrochloride the same as clindamycin hydrochloride?

No. Clindamycin palmitate hydrochloride is an ester prodrug used in oral pediatric products. Clindamycin hydrochloride is a salt form generally associated with oral capsule products. Both deliver clindamycin but differ in formulation properties and dosage forms.

Can a clindamycin palmitate suspension be made sugar-free?

Yes. A sugar-free suspension is technically feasible using polyols and high-intensity sweeteners, but the sponsor must control hygroscopicity, viscosity, microbial preservation, taste, and powder flow.

What is the best excipient for masking clindamycin bitterness?

No single excipient is consistently sufficient. The strongest approach usually combines a sweetener system, flavor, suspension control, and a particle or polymer-based taste-masking method validated through sensory testing.

Can a clindamycin palmitate product receive new patent protection?

Yes, but protection would generally need to cover a novel formulation, process, packaging system, or dosing device with demonstrated technical performance. Routine substitution of one conventional sweetener or preservative is unlikely to create a strong patent position.

Is a ready-to-use clindamycin palmitate liquid commercially attractive?

It can be attractive for selected institutional and specialty channels, but it carries higher stability, preservation, packaging, and manufacturing risk than a dry powder for reconstitution.

References

1. DailyMed. (n.d.). Cleocin Pediatric: Clindamycin palmitate hydrochloride powder, for solution. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Food and Drug Administration. (2019). ANDA submissions: Refuse-to-receive standards guidance for industry. FDA.

5. U.S. Food and Drug Administration. (2022). Product-specific guidances for generic drug development. FDA.

6. International Council for Harmonisation. (2009). Q8(R2) pharmaceutical development. ICH.

7. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.